Event context and recent share performance

Merit Medical Systems (MMSI) shares have come under pressure recently, with the stock showing a 2.4% decline over the past day, 4.6% over the past week, and deeper pullbacks over the past month and past 3 months.

The recent pullback, including a 30 day share price return of 18.9% decline and a year to date share price return of 22.8% decline, sits alongside a 1 year total shareholder return of 34.4% decline. This suggests momentum has been fading despite earlier 5 year gains.

If you are weighing what to do next after this healthcare move, it could be a good moment to broaden your search and check out 35 healthcare AI stocks

With Merit Medical now trading at US$66.71, a value score of 2, an indicated 18.2% intrinsic discount, and a large gap to the US$102 analyst target, is this healthcare pullback a buying opportunity, or is the market already pricing in future growth?

Price-to-Earnings of 30.9x: Is it justified?

On a P/E of 30.9x, Merit Medical Systems trades at a higher valuation than many peers, even after the recent share price pullback to $66.71. For context, the US Medical Equipment industry sits at 26.9x and the peer group average is 16.4x, while the estimated fair P/E for the company is 24.9x.

The P/E ratio compares the current share price to earnings per share and is often used to gauge how much investors are paying for each dollar of profit. For a healthcare equipment name with $1,515.91m in revenue and $128.49m in net income, a higher P/E can reflect expectations for continued earnings growth, but it also raises the bar for future performance.

Here, the market is assigning Merit Medical a premium to both the industry and peer averages, as well as to the estimated fair P/E level the market could move towards over time. That gap suggests investors are currently paying more for each dollar of earnings than they would for many comparable companies.

Result: Price-to-Earnings of 30.9x (OVERVALUED)

However, recent share price weakness and a P/E premium to both industry and peer averages could limit upside if revenue or net income growth slows from current levels.

Another view: DCF suggests a different story

While the 30.9x P/E points to an expensive stock, the SWS DCF model paints a different picture. With MMSI trading at $66.71 versus an estimated future cash flow value of $81.59, the shares screen as 18.2% undervalued. Which signal do you treat as more important?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Merit Medical Systems for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 53 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

The mixed signals in this review might leave you unsure, so this is a good time to move quickly, consider the numbers on your own, and see why some investors are still focusing on 4 key rewards

Looking for more investment ideas?

If Merit Medical is on your radar, broaden your watchlist now, because some of the most interesting opportunities may sit in very different corners of the market.

• Target steadier potential by checking companies that appear financially resilient in the solid balance sheet and fundamentals stocks screener (39 results).
• Spot opportunities that look cheaper than their quality suggests through the 53 high quality undervalued stocks.
• Seek shares offering higher income potential with the 13 dividend fortresses.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.